Skip to content

Join our newsletter

Donate to MPN-CC

Menu
MPN Cancer Connection logo
Your Future Matters
  • Understanding MPNs
    • General Information
    • An Overview of Myeloproliferative Neoplasms
    • What is Myelofibrosis?
    • What is Polycythemia Vera
    • What is Essential Thrombocythemia
  • Clinical Trials
    • Clinical Trial Finder
    • Search for Clinical Trials
    • Clinical Trial Acronyms and Abbreviations
    • Understanding the Phases of Clinical Trials
  • Our Impact
    • Donate
  • About
    • About Us
    • Our Founder
    • Our Mission
    • MPN-CC Team
    • Corporate Sponsors
  • Resources
    • Patient Resources
    • MPN Experts
    • Advocacy Partners
    • MPN Websites
    • Facebook Groups
    • Treatments
      • Ojjaara
      • Vonjo
      • BESREMi
      • Jakafi
      • INREBIC
  • Blog
    • Blog
  • Contact
Close Menu

MPN Clinical Trial Finder

Clinical Trial Finder

Search Results

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Study Purpose

The purpose of this study is to learn about the impact that the services and programs provided by the Leukemia and Lymphoma Society have among patients with blood cancer, such as access to care, quality of life, and financial burden.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Interventional
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Be currently receiving primary or relapse treatment for a diagnosis of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) - Report experiencing at least one unmet need addressed by the LLS Program (i.e., medical care including second opinions, travel for care, clinical trial access, financial and insurance needs, supportive programs, disease and treatment education) - Not be currently participating in any LLS programs or services.
  • - Be willing to be followed for 6 months.
  • - Speak English or Spanish.

Exclusion Criteria:

  • - Are not receiving primary or relapse treatment for a diagnosis of leukemia, lymphoma, myeloma, myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN) - Are not experiencing unmet needs addressed by the LLS Program (i.e., medical care including second opinions, travel for care, clinical trial access, financial and insurance needs, supportive programs, disease and treatment education) - Are currently participating in any LLS programs or services.
  • - Are not willing to be followed for 6 months.
  • - Do not speak English or Spanish.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05745285
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

N/A
Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

University of Miami
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Frank Penedo, PhD
Principal Investigator Affiliation University of Miami
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Other
Overall Status Not yet recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Arms & Interventions

Arms

Experimental: LLS Program and Usual Care Group

Participants in the LLS Program and Usual Care condition will receive LLS services such as information, services, and financial aid so that patients can have better access to healthcare and better quality of life. Participants will also receive the standard care. Participants will be in this group for 6 months.

No Intervention: Usual Care Group

Participants will receive the standard care. Participants will be in this group for 6 months.

Interventions

Other: - LLS Program

The intervention will be conducted virtually. Participants will receive LLS's free patient and caregiver services including co-pay assistance, transportation and urgent need assistance, a scholarship program for young adult patients and survivors, one-on-one peer-to-peer support, online chats and support groups facilitated by clinical social workers, and nutrition counseling with a registered dietician for 6 months.

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Sylvester Comprehensive Cancer Center, Miami, Florida

Status

Address

Sylvester Comprehensive Cancer Center

Miami, Florida, 33136

Site Contact

Madeline Krause, MSEd

[email protected]

305-243-3329

Chicago, Illinois

Status

Address

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

Site Contact

Mariam Nawas, MD

[email protected]

773-702-6149

San Antonio, Texas

Status

Address

Mays Cancer Center at UT Health San Antonio

San Antonio, Texas, 78229

Site Contact

Patricia Chalela, DrPH

[email protected]

210-562-6513

Powered By
The content provided on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation.

MPN CANCER CONNECTION

is a 501 (c) (3) non-profit public charity, our tax ID number is 47-4839850.

Privacy Policy

Copyright © 2024 MPN Cancer Connection,
All Rights Reserved

Follow us on Social

RSS PV Reporter News

  • Honor those who make a difference in the myeloproliferative neoplasm community: Submit a nomination to the MPN Heroes® Recognition Program today!
  • Precision Medicine in Myeloproliferative Neoplasms (MPNs): Molecular Insights and Advances
  • What Rare Disease Day Means to Me

Recent News

  • Myelofibrosis Treatment: Optimizing JAK Inhibitor Strategies in 2024
  • MPN Research 2024: Emerging Trends

JOIN OUR NEWSLETTER

There was an error. Please try again later.

Success!

  • Sponsors
  • Impact
  • Partners
  • About
  • Contact
  • NCCN Guidelines
  • Terms
  • Privacy

Site by: Kaleidoscopic